AU Patent

AU2014321456B2 — Combination drug therapy

Assigned to GlaxoSmithKline LLC · Expires 2018-05-24 · 8y expired

What this patent protects

A novel combination comprising the androgen receptor inhibitor, 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-

USPTO Abstract

A novel combination comprising the androgen receptor inhibitor, 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-

Drugs covered by this patent

Patent Metadata

Patent number
AU2014321456B2
Jurisdiction
AU
Classification
—
Expires
2018-05-24
Drug substance claim
No
Drug product claim
No
Assignee
GlaxoSmithKline LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.